Onyx Pharmaceuticals Inc. (NYSE: ONXX), a developer of cancer therapies, were up $2.40 to $51.75 in pre-open trading. ONXX released Q3 Nexavar sales of $105 million, beating Street expectations. Wachovia says, "With the ONXX/Bayer Nexavar joint venture touching profitability two quarters earlier than anticipated, we believe Street expectations for a Bayer acquisition of ONXX." ONXX has projected the next key clinical event will be in the 2nd half of 2008 for Phase 3 non-small cell lung cancer. ONXX over all option implied volatility of 58 is near its 26-week average of 55 according to Track Data, suggesting larger price risks.
Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.
New Facebook share structure hints at IPO
Before the bell: Futures higher ahead of housing, jobless data
Nuclear power is on the comeback trail
